BOSTON SCIENTIFIC CORP
BSXAPI behind this page
BSX Q3 2025 request
Playground key active
/api/financials?ticker=BSX&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 5,065 | 4,209 | +20.3% |
Show Product Lines breakouts |
|||
| Cardiac Rhythm Management [Member] | 578 | 561 | +3.0% |
| Cardiac Rhythm Management [Member] · Non Us | 224 | 213 | +5.2% |
| Cardiac Rhythm Management [Member] · US | 354 | 349 | +1.4% |
| Cardiology [Member] | 2,641 | 2,129 | +24.0% |
| Cardiology [Member] · Non Us | 954 | 859 | +11.1% |
| Cardiology [Member] · US | 1,687 | 1,269 | +32.9% |
| Electrophysiology [Member] | 865 | 527 | +64.1% |
| Electrophysiology [Member] · Non Us | 258 | 160 | +61.3% |
| Electrophysiology [Member] · US | 607 | 366 | +65.8% |
| Endoscopy [Member] | 747 | 678 | +10.2% |
| Endoscopy [Member] · Non Us | 285 | 261 | +9.2% |
| Endoscopy [Member] · US | 462 | 417 | +10.8% |
| Interventional Cardiology Therapies | 686 | 661 | +3.8% |
| Interventional Cardiology Therapies · Non Us | 429 | 449 | -4.5% |
| Interventional Cardiology Therapies · US | 256 | 212 | +20.8% |
| Neuromodulation [Member] | 293 | 268 | +9.3% |
| Neuromodulation [Member] · Non Us | 63 | 57 | +10.5% |
| Neuromodulation [Member] · US | 230 | 211 | +9.0% |
| Peripheral Interventions [Member] | 702 | 602 | +16.6% |
| Peripheral Interventions [Member] · Non Us | 297 | 285 | +4.2% |
| Peripheral Interventions [Member] · US | 405 | 316 | +28.2% |
| Urology [Member] | 682 | 532 | +28.2% |
| Urology [Member] · Non Us | 171 | 153 | +11.8% |
| Urology [Member] · US | 511 | 379 | +34.8% |
| Watchman | 512 | 380 | +34.7% |
| Watchman · Non Us | 43 | 38 | +13.2% |
| Watchman · US | 470 | 342 | +37.4% |
Show Business Segments breakouts |
|||
| BSX Reportable Segments [Member] · Asia Pacific | 802 | 684 | +17.3% |
| BSX Reportable Segments [Member] · EMEA | 793 | 773 | +2.6% |
| BSX Reportable Segments [Member] · Latin America and Canada [Member] | 175 | 159 | +10.1% |
| BSX Reportable Segments [Member] · US | 3,294 | 2,593 | +27.0% |
| Cardiovascular | 3,343 | 2,731 | +22.4% |
| Cardiovascular · Non Us | 1,251 | 1,145 | +9.3% |
| Cardiovascular · US | 2,092 | 1,586 | +31.9% |
| MedSurg | 1,722 | 1,479 | +16.4% |
| MedSurg · Non Us | 519 | 472 | +10.0% |
| MedSurg · US | 1,202 | 1,007 | +19.4% |
Show Geography breakouts |
|||
| Emerging Markets [Member] | 765 | 684 | +11.8% |
| Non Us | 1,770 | 1,616 | +9.5% |
| US | 3,294 | 2,593 | +27.0% |
| Cost of Revenue | 1,523 | 1,312 | +16.1% |
| Gross Profit | 3,542 | 2,897 | +22.3% |
| Selling, General & Administrative | 1,741 | 1,562 | +11.5% |
| Research And Development Expense Excluding Acquired In Process Cost | 514 | 407 | +26.3% |
| Royalty Expense | 12 | 5 | +140.0% |
| Amortization Of Intangible Assets | 225 | 205 | +9.8% |
| Impairment Of Intangible Assets Excluding Goodwill | 0 | — | — |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 11 | -23 | +147.8% |
| Restructuring Charges | -8 | 8 | -200.0% |
| Operating Expenses | 2,494 | 2,164 | +15.2% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 282 | 234 | +20.5% |
| Operating Income | 1,048 | 733 | +43.0% |
| Interest Expense | -87 | -79 | -10.1% |
| Other Nonoperating Income Expense Net | -23 | 14 | -264.3% |
| Income Before Taxes | 939 | 669 | +40.4% |
| Income Tax Expense (Benefit) | 183 | 200 | -8.5% |
| Net Income | 755 | 468 | +61.3% |
Show Equity Components breakouts |
|||
| Retained Earnings | 755 | 468 | +61.3% |
| Net Income Loss Attributable To Noncontrolling Interest | 0 | 0 | — |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 0 | 0 | — |
| Retained Earnings | 0 | 0 | — |
| Net Income Loss Available To Common Stockholders Basic | 755 | 469 | +61.0% |
| EPS (Basic) | 0.51 | 0.32 | +59.4% |
| EPS (Diluted) | 0.51 | 0.32 | +59.4% |
| Wtd Avg Shares (Basic) | 1,481.7 | 1,472.7 | +0.6% |
| Wtd Avg Shares (Diluted) | 1,495.5 | 1,487.4 | +0.5% |
| Other Non-Operating Income (Expense) | -110 | -65 | -69.2% |
| Comprehensive Income | 788 | 177 | +345.2% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract · Designated As Hedging Instrument | 69 | -66 | +204.5% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show Hedging Designation breakouts |
|||
| Nondesignated · Other Nonoperating Income Expense | -2 | 44 | -104.5% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,275 | 2,502 | -49.0% |
| Accounts Notes And Loans Receivable Net Current | 2,828 | 2,501 | +13.1% |
| Inventory | 2,921 | 2,753 | +6.1% |
| Prepaid Taxes | 310 | 332 | -6.6% |
| Prepaid Expenses & Other Current Assets | 701 | 674 | +4.0% |
| Total Current Assets | 8,035 | 8,761 | -8.3% |
| Non-Current Assets | |||
| Goodwill | 18,214 | — | — |
Show Business Segments breakouts |
|||
| Cardiovascular | 10,528 | — | — |
| MedSurg | 7,686 | — | — |
Show Business Acquisition breakouts |
|||
| All Other | 408 | — | — |
| Deferred Tax Assets | 3,669 | 3,816 | -3.9% |
| Other Non-Current Assets | 1,832 | 1,642 | +11.6% |
| Total Assets | 42,707 | 38,078 | +12.2% |
| Property, Plant & Equipment | 3,795 | — | — |
| Operating Lease Right-of-Use Assets | 495 | — | — |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 3,795 | — | — |
| Intangible Assets Net Excluding Goodwill | 7,162 | — | — |
| Current Liabilities | |||
| Debt Current | 483 | — | — |
| Accounts Payable | 1,002 | 907 | +10.5% |
| Accrued Liabilities | 2,981 | 2,460 | +21.2% |
| Other Liabilities Current | 862 | 891 | -3.3% |
| Total Current Liabilities | 5,328 | 5,910 | -9.8% |
| Deferred Revenue | 309 | 290 | +6.6% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 242 | 138 | +75.4% |
| Other Non-Current Liabilities | 2,390 | 1,841 | +29.8% |
| Long-Term Debt (Q) | — | — | — |
Show Long-Term Debt Type breakouts |
|||
| December 2027 Notes | 900 | — | — |
| Financial Lease Obligation | 125 | — | — |
| January 2040 Notes | 300 | — | — |
| June 2030 Notes | 1,200 | — | — |
| March 2028 Notes | 344 | — | — |
| March 2028 Senior Notes | 880 | — | — |
| March 2029 Euro Senior Notes | 880 | — | — |
| March 2029 Notes | 272 | — | — |
| March 2031 Notes | 880 | — | — |
| March 2031 Notes 2 | 997 | — | — |
| March 2032 Euro Senior Notes | 1,466 | — | — |
| March 2034 Notes | 586 | — | — |
| March 2034 Notes 2 | 762 | — | — |
| March 2039 Notes | 450 | — | — |
| March 2049 Notes | 650 | — | — |
| November 2035 Notes | 350 | — | — |
| Senior Notes | 11.33 | — | — |
| Operating Lease Liabilities | 445 | 373 | +19.3% |
| Accrued Income Taxes Noncurrent | 403 | 364 | +10.7% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 11,117 | — | — |
| Stockholders' Equity | |||
| Common Stock | 17 | 17 | 0.0% |
| Treasury Stock Value | -2,251 | -2,251 | 0.0% |
| Additional Paid In Capital Common Stock | 21,419 | 20,963 | +2.2% |
| Retained Earnings | 4,899 | 2,107 | +132.5% |
| Accumulated Other Comprehensive Income | -689 | -128 | -438.3% |
| Total Stockholders' Equity | 23,394 | 20,708 | +13.0% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -17 | -8 | -112.5% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -83 | 59 | -240.7% |
| Accumulated Other Comprehensive Income | -689 | -128 | -438.3% |
| Accumulated Translation Adjustment | -589 | -179 | -229.1% |
| Minority Interest | 236 | 248 | -4.8% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 23,630 | 20,956 | +12.8% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -689 | -128 | -438.3% |
| Additional Paid In Capital | 21,419 | 20,963 | +2.2% |
| Common Stock | 17 | 17 | 0.0% |
| Noncontrolling Interest | 236 | 248 | -4.8% |
| Parent | 23,394 | 20,708 | +13.0% |
| Retained Earnings | 4,899 | 2,107 | +132.5% |
| Treasury Stock Common | -2,251 | -2,251 | 0.0% |
| Total Liabilities & Equity | 42,707 | 38,078 | +12.2% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 1,003 | 921 | +8.9% |
| Cash Flow Impact Of Deferred Income Tax Expense Benefit | 20 | 10 | +100.0% |
| Stock-Based Compensation | 228 | 197 | +15.7% |
| Goodwill And Intangible Asset Impairment | 46 | 276 | -83.3% |
| Gain Loss On Investments | -181 | 60 | -401.7% |
| Inventory Step Up Amortization | 127 | — | — |
| Tangible Asset Impairment Charges | 73 | 30 | +143.3% |
| Other Operating Activities Cash Flow Statement | 22 | -8 | +375.0% |
| Change in Accounts Receivable | -171 | -261 | +34.5% |
| Change in Inventory | -138 | -274 | +49.6% |
| Increase Decrease In Other Operating Assets | -103 | -109 | +5.5% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 11 | -142 | +107.7% |
| Net Cash from Operations | 3,170 | 1,979 | +60.2% |
| Investing Activities | |||
| Capital Expenditures | -525 | -513 | -2.3% |
| Payments To Acquire Businesses Net Of Cash Acquired | -1,504 | -1,222 | -23.1% |
Show Business Acquisition breakouts |
|||
| All Other | -593 | — | — |
| Payments To Acquire Businesses Net Of Cash Acquired (Q) | — | — | — |
Show Business Acquisition breakouts |
|||
| Q3 2025 Acquisition | -73 | — | — |
| Proceeds From Payments For Investments And Acquisitions Of Certain Technologies | -180 | -264 | +31.8% |
| Proceeds From Settlements Of Hedge Contracts | 69 | — | — |
| Other Investing Activities | 11 | 17 | -35.3% |
| Net Cash from Investing | -2,128 | -1,983 | -7.3% |
| Financing Activities | |||
| Payment For Contingent Consideration Liability Financing Activities | -62 | -131 | +52.7% |
| Finance Lease Principal Payments | -49 | -25 | -96.0% |
| Repayments Of Short Term Debt | -1,595 | -504 | -216.5% |
| Proceeds From Repayments Of Commercial Paper | -196 | — | — |
| Proceeds From Issuance Of Senior Long Term Debt | 1,558 | 2,145 | -27.4% |
Show Long-Term Debt Type breakouts |
|||
| 2025 Eurobond Offering SNs | 1.56 | — | — |
| Paymenttonetsharesettleemployeeequityawards | -128 | -83 | -54.2% |
| Proceeds From Stock Plans | 262 | 202 | +29.7% |
| Proceeds From Payments For Other Financing Activities | -2 | -4 | +50.0% |
| Net Cash from Financing | -211 | 1,600 | -113.2% |
| Supplemental | |||
| Fair Value Of Contingent Consideration Recorded In Purchase Accounting | 258 | 29 | +789.7% |
| Right Of Use Asset Obtained In Exchange For Finance Lease Liability | 195 | — | — |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 39 | -2 | +2050.0% |
| Net Change in Cash | 870 | 1,594 | -45.4% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,476 | 2,649 | -44.3% |
| Restricted Cash And Cash Equivalents At Carrying Value | 98 | 70 | +40.0% |
| Restricted Cash Equivalents Noncurrent | 103 | 78 | +32.1% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.